{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:41:10Z","timestamp":1773808870679,"version":"3.50.1"},"reference-count":38,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T00:00:00Z","timestamp":1640649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Prostate cancer (PCa) is one of the most frequent cancer in male population. Androgen deprivation therapy is the first-line strategy for the metastatic stage of the disease, but, inevitably, PCa develops resistance to castration (CRPC), becoming incurable. In recent years, clinical trials are testing the efficacy of anti-CTLA4 on CRPC. However, this tumor seems to be resistant to immunotherapies that are very effective in other types of cancers, and, so far, only the dendritic cell vaccine sipuleucel-T has been approved. In this work, we employ a mathematical model of CRPC to determine the optimal administration protocol of ipilimumab, a particular anti-CTLA4, as single treatment or in combination with the sipuleucel-T, by considering both the effect on tumor population and the drug toxicity. To this end, we first introduce a dose-depending function of toxicity, estimated from experimental data, then we define two different optimization problems. We show the results obtained by imposing different constraints, and how these change by varying drug efficacy. Our results suggest administration of high-doses for a brief period, which is predicted to be more efficient than solutions with prolonged low-doses. The model also highlights a synergy between ipilimumab and sipuleucel-T, which leads to a better tumor control with lower doses of ipilimumab. Finally, tumor eradication is also conceivable, but it depends on patient-specific parameters.<\/jats:p>","DOI":"10.3390\/cancers14010135","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T06:55:03Z","timestamp":1640674503000},"page":"135","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Model-Based Framework to Identify Optimal Administration Protocols for Immunotherapies in Castration-Resistance Prostate Cancer"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3402-7717","authenticated-orcid":false,"given":"Roberta","family":"Coletti","sequence":"first","affiliation":[{"name":"Fondazione The Microsoft Research, University of Trento Centre for Computational and Systems Biology (COSBI), 38068 Rovereto, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3512-8560","authenticated-orcid":false,"given":"Andrea","family":"Pugliese","sequence":"additional","affiliation":[{"name":"Department of Mathematics, University of Trento, 38123 Trento, Italy"}]},{"given":"Andrea","family":"Lunardi","sequence":"additional","affiliation":[{"name":"Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, 38123 Trento, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7968-2531","authenticated-orcid":false,"given":"Orazio","family":"Caffo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Santa Chiara Hospital, 38122 Trento, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9043-7705","authenticated-orcid":false,"given":"Luca","family":"Marchetti","sequence":"additional","affiliation":[{"name":"Fondazione The Microsoft Research, University of Trento Centre for Computational and Systems Biology (COSBI), 38068 Rovereto, Italy"},{"name":"Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, 38123 Trento, Italy"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMra1701695","article-title":"Metastatic Prostate Cancer","volume":"378","author":"Sartor","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.seminoncol.2018.10.001","article-title":"Current therapeutic options in metastatic castration-resistant prostate cancer","volume":"45","author":"Ingrosso","year":"2018","journal-title":"Semin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41585-021-00470-4","article-title":"Treatment and trials in non-metastatic castration-resistant prostate cancer","volume":"18","author":"Lokeshwar","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.2147\/OTT.S228355","article-title":"Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape","volume":"13","author":"Hall","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3747\/co.27.5223","article-title":"A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/14737140.2016.1211936","article-title":"Ipilimumab in melanoma","volume":"16","author":"Specenier","year":"2016","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4861570","DOI":"10.1155\/2017\/4861570","article-title":"Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review","volume":"2017","author":"Janiczek","year":"2017","journal-title":"J. Immunol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/14712598.2018.1420777","article-title":"Ipilimumab for the treatment of metastatic prostate cancer","volume":"18","author":"Alaia","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Phan, T., Crook, S.M., Bryce, A.H., Maley, C.C., Kostelich, E.J., and Kuang, Y. (2020). Review: Mathematical Modeling of Prostate Cancer and Clinical Application. Appl. Sci., 10.","DOI":"10.3390\/app10082721"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Irurzun-Arana, I., Janda, A., Ardanza-Trevijano, S., and Troc\u00f3niz, I.F. (2018). Optimal dynamic control approach in a multi-objective therapeutic scenario: Application to drug delivery in the treatment of prostate cancer. PLoS Comput. Biol., 14.","DOI":"10.1371\/journal.pcbi.1006087"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"21599","DOI":"10.1038\/srep21599","article-title":"Prediction of treatment efficacy for prostate cancer using a mathematical model","volume":"6","author":"Peng","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9063","DOI":"10.1038\/s41598-020-65590-0","article-title":"A QSP model of prostate cancer immunotherapy to identify effective combination therapies","volume":"10","author":"Coletti","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"110500","DOI":"10.1016\/j.jtbi.2020.110500","article-title":"Modeling the effect of immunotherapies on human castration-resistant prostate cancer","volume":"509","author":"Coletti","year":"2021","journal-title":"J. Theor. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0300-483X(95)03222-2","article-title":"Physiologically based pharmacokinetic\/pharmacodynamic modeling of chemical mixtures and possible applications in risk assessment","volume":"105","author":"Thomas","year":"1995","journal-title":"Toxicology"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lee, D.S., Kim, S.J., Choi, G.W., Lee, Y.B., and Cho, H.Y. (2018). Pharmacokinetic\u2013Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats. Molecules, 23.","DOI":"10.3390\/molecules23040909"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"16353","DOI":"10.1016\/j.ifacol.2020.12.666","article-title":"Toxicity-Centric Cancer Chemotherapy Treatment Design","volume":"53","author":"Liparulo","year":"2020","journal-title":"IFAC-PapersOnLine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1006\/cbmr.2000.1540","article-title":"Optimizing Drug Regimens in Cancer Chemotherapy by an Efficacy\u2013Toxicity Mathematical Model","volume":"33","author":"Iliadis","year":"2000","journal-title":"Comput. Biomed. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0010-4825(00)00032-9","article-title":"Optimizing drug regimens in cancer chemotherapy: A simulation study using a PK\u2013PD model","volume":"31","author":"Barbolosi","year":"2001","journal-title":"Comput. Biol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1109\/TBME.2013.2280189","article-title":"Mathematical Modeling of Tumor Growth, Drug-Resistance, Toxicity, and Optimal Therapy Design","volume":"61","author":"Hadjiandreou","year":"2014","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","article-title":"A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phase I\/II study","volume":"24","author":"Slovin","year":"2013","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00262-008-0653-8","article-title":"Ipilimumab: Controversies in its development, utility and autoimmune adverse events","volume":"58","author":"Weber","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(12)70006-2","article-title":"Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial","volume":"13","author":"Madan","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_29","unstructured":"Goldberg, D.E. (1989). Genetic Algorithms in Search, Optimization and Machine Learning, Addison-Wesley Longman Publishing Co., Inc."},{"key":"ref_30","unstructured":"The MathWorks Inc. (2019). MATLAB. Version R2019b, The MathWorks Inc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/cancers4020420","article-title":"Immune response to sipuleucel-T in prostate cancer","volume":"4","author":"Thara","year":"2012","journal-title":"Cancers"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrd3463","article-title":"Ipilimumab","volume":"10","author":"Sondak","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1200\/JCO.2018.36.6_suppl.368","article-title":"Survival after sipuleucel-T (SIP-T) and low-dose ipilimumab (IPI) in men with metastatic, progressive, castrate-resistant prostate cancer (M-CRPC)","volume":"36","author":"Ku","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/ITT.S122497","article-title":"Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer","volume":"6","author":"Scholz","year":"2017","journal-title":"ImmunoTargets Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons jointly applied","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann. Appl. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e00149","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: Current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_37","first-page":"1001","article-title":"Global dynamics of a model of joint hormone treatment with dendritic cell vaccine for prostate cancer","volume":"22","author":"Rutter","year":"2017","journal-title":"Discret. Contin. Dyn. Syst.\u2014Ser. B"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kronik, N., Kogan, Y., Elishmereni, M., Halevi-Tobias, K., Vuk-Pavlovi\u0107, S., and Agur, Z. (2010). Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0015482"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/1\/135\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:54:45Z","timestamp":1760169285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/1\/135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,28]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["cancers14010135"],"URL":"https:\/\/doi.org\/10.3390\/cancers14010135","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,28]]}}}